Admelog

Admelog is a rapid-acting insulin analog used to improve blood sugar control in adults and children with diabetes mellitus. It is a biosimilar to insulin lispro, which means it is highly similar to an already approved biological medicine. Admelog is manufactured by Sanofi and was approved by the Food and Drug Administration (FDA) in 2017.

Medical Uses

Admelog is indicated for the treatment of type 1 diabetes in adults and children and type 2 diabetes in adults. It is typically administered via subcutaneous injection and can be used in insulin pumps for continuous subcutaneous insulin infusion (CSII). Admelog is designed to be taken shortly before meals to manage postprandial blood glucose levels.

Mechanism of Action

Admelog works by mimicking the action of natural insulin. It facilitates the uptake of glucose into cells, particularly in the liver, muscle, and fat tissue, thereby lowering blood glucose levels. The onset of action for Admelog is approximately 15 minutes, with a peak effect occurring between 30 minutes to 1 hour, and a duration of action of about 2 to 4 hours.

Administration

Admelog is administered via subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection site should be rotated within the same region to reduce the risk of lipodystrophy. It can also be administered using an insulin pump for continuous delivery.

Side Effects

Common side effects of Admelog include hypoglycemia, injection site reactions, and allergic reactions. Severe hypoglycemia can lead to symptoms such as confusion, seizures, and loss of consciousness. Patients are advised to monitor their blood glucose levels regularly to avoid hypoglycemia.

Storage

Unopened Admelog vials and pens should be stored in a refrigerator between 36°F to 46°F (2°C to 8°C). Once opened, they can be kept at room temperature, below 86°F (30°C), and should be used within 28 days.

Related Pages

• Insulin
• Diabetes mellitus
• Type 1 diabetes
• Type 2 diabetes
• Insulin lispro
• Sanofi
• Hypoglycemia